DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the PE ratio of Remedium Lifecare Ltd?

Remedium Lifecare Ltd has a price-to-earnings (PE) ratio of 16.0 in the Commercial Services sector.

What is the market capitalisation of Remedium Lifecare Ltd?

Remedium Lifecare Ltd has a market capitalisation of approximately ₹27 crore.

Remedium Lifecare Ltd

REMEDIUMFECARELTD·NSE·Commercial Services

₹0.00▲ +0.00 (+0.00%)

⚠️Trading suspended. Not a live price.

Commercial Services · Trading & Distributors

Carries meaningful debt — watch the balance sheet

52W₹0

₹2-16%

Open

—

High

—

Low

—

Prev Close

—

Volume

—

VWAP

—

Snapshot

Key fundamentals

Market Cap

₹27 Cr

P/E Ratio

16.00Fair

P/B Ratio

0.31

EPS

₹0.02

Book Value

₹1.04

ROE

4.85%Weak

ROCE

22.04%Efficient

Dividend Yield

0.00%

Debt / Equity

25.93High

Face Value

₹1.00

52W High

₹1.80

52W Low

₹0.25

Sector

Commercial Services

Industry

Trading & Distributors

Expensive

None moatVery High uncertainty

Fair value estimate

₹1

No recent traded price

BearFair valueBull

₹1₹1₹1

/100

Business quality — Watch the fundamentals

Growth 50Profitability 0Efficiency 70Valuation 43

Plain English

Our view

Carries meaningful debt — watch the balance sheet
Capital is working hard (ROCE 22%)
High leverage — debt exceeds 1.5× equity

Strengths

Capital is working hard (ROCE 22%)

Risks

High leverage — debt exceeds 1.5× equity
Weak returns on equity (5%)

How we got there

Fair value methods

Residual income

5% ROE fading to 15% over ~3 yrs, on ₹1 book

₹1

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹1

Analyst target

No analyst coverage

—

Blended fair value₹1

What the numbers say

Investment thesis

Bull case

Capital is working hard (ROCE 22%)

Bear case

High leverage — debt exceeds 1.5× equity
Weak returns on equity (5%)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

16.0Fair

Below 15× is value territory; above 35× prices in strong growth

ROE

4.8%Weak

Above 15% is considered healthy for Indian equities

ROCE

22.0%Efficient

Above 18% means capital is working hard

Debt/Eq

25.93High

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹27 Cr

P/B

0.31

EPS

₹0.02

Div Yield

—

What changed

Recent changes

Foreign investors+1.7% stake last quarter

What matters

News impact

Overview

Valuation

Attractive

P/E 16.0×

Growth

N/A

No history

Profitability

Modest

4.8% ROE

Financial health

High debt

D/E 25.93

Momentum

N/A

No technicals

Today

Trading activity

Delivery %—

Turnover—

Trades—

VWAP—

Face value₹1.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

No growth history

Not enough annual history to compute CAGR.

Profile

Pros

Stock is trading at 0.26 times its book value

Watch-outs

Cons

Company has low interest coverage ratio.
Promoter holding is low: 1.13%
Earnings include an other income of Rs.10.8 Cr.
Company has high debtors of 695 days.

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 Dec 2025

Foreign investors bought 1.70 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

Promoter

Promoters

1.1%0.00

Public

81.3%+2.27

FII / FPI

1.7%+1.70

DII

0.0%0.00

Others

15.9%

Total shareholders

1,11,269-2,850 QoQ

Quarterly trend

Ownership over time

Q3 FY26

Promoter1.13%

FII1.70%

Public81.29%

Others15.88%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Incorporated in 1988, Remedium Lifecare Ltd is in the business of trading in Advanced Pharmaceutical Intermediates and other pharma products